This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Derma Sciences Reports Third Quarter 2012 Financial Results

Stocks in this article: DSCI

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2012. Highlights of the third quarter of 2012 and recent weeks include:

  • Net sales were $19.6 million, up 24% over the prior-year third quarter and up 12% over the second quarter of 2012
  • Advanced wound care product sales were $6.8 million, up 67% over the prior-year third quarter and up 18% over the second quarter of 2012
  • Excluding $1.8 million of Total Contact Cast (TCC) direct sales resulting from the MedEfficiency acquisition, advanced wound care product sales were up 36% compared with the prior-year third quarter and up 15% over the second quarter of 2012
  • Advanced wound care products accounted for 35% of net sales, up from 26% of net sales a year ago
  • Traditional wound care product sales were $12.8 million, up 9% from the prior-year third quarter and up 9% over the second quarter of 2012
  • Gross margin was 35.2%, an increase of 5.2 percentage points over gross margin of 30.0% for the third quarter of 2011
  • Net loss was $3.1 million or $0.24 per share, compared with a net loss of $0.8 million or $0.08 per share in the prior-year third quarter, reflecting higher research and development expense and expenses related to advanced wound care growth
  • Held a positive and constructive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA)
  • Launched MEDIHONEY® HCS (Hydrogel Colloidal Sheet) in the U.S. and featured the product at a key medical conference
  • Reached the significant $10.0 million sales milestone for MEDIHONEY, triggering a $1.0 million payment to Comvita New Zealand Ltd.
  • Strengthened ownership of key brands with an exclusive global license to the NIMBUS® antimicrobial technology available in BIOGUARD® dressings

Management Commentary

“This was an outstanding quarter across our various business segments with our financial performance exceeding expectations,” said Edward J. Quilty, chief executive officer of Derma Sciences. “We are executing on our plan to make Derma Sciences into a leading provider of wound care solutions, especially for chronic conditions, and our revenue growth for the third quarter provides tangible evidence of the soundness of our plan and confirmation of our progress.

1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs